JANX · Company research

Janux Therapeutics, Inc. (JANX): Stock News & Events

Recent company-linked news records available in the database.

RESEARCH CONTEXT

Understand the numbers

Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.

16records availableHealthcare

Stock News & Events data

Database-backed records only

16 rows
titlesummaryurlsourcepublished atsentimentsentiment scorerelevance score
Janux Therapeutics, Inc. (JANX) stock price, news, quote and history - Yahoo Finance AustraliaJanux Therapeutics, Inc. (JANX) stock price, news, quote and history Yahoo Finance AustraliaView source ↗Yahoo Finance AustraliaOct 15, 2026neutral00.6
Janux Therapeutics, Inc. (JANX) Stock Price, News, Quote & History - Yahoo! Finance CanadaJanux Therapeutics, Inc. (JANX) Stock Price, News, Quote & History Yahoo! Finance CanadaView source ↗Yahoo! Finance CanadaOct 14, 2026neutral00.6
Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now? - Yahoo FinanceJanux Therapeutics (JANX), What Is Drawing Fresh Attention Now? Yahoo FinanceView source ↗Yahoo FinanceOct 13, 2026neutral00.6
Janux Therapeutics, Inc. (JANX) stock price, news, quote and history - Yahoo Finance UKJanux Therapeutics, Inc. (JANX) stock price, news, quote and history Yahoo Finance UKView source ↗Yahoo Finance UKOct 11, 2026neutral00.6
Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run - Yahoo FinanceJanux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run Yahoo FinanceView source ↗Yahoo FinanceOct 10, 2026neutral00.6
Janux Therapeutics (JANX) Stock Dropped, So What Is Behind The Latest Attention? - Simply Wall StreetJanux Therapeutics (JANX) Stock Dropped, So What Is Behind The Latest Attention? Simply Wall StreetView source ↗Simply Wall StreetSep 24, 2026neutral00.6
Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions - Simply Wall StreetJanux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions Simply Wall StreetView source ↗Simply Wall StreetSep 23, 2026neutral00.6
The first patient gets Janux's new immune treatment in a prostate cancer trial. - Stock TitanThe first patient gets Janux's new immune treatment in a prostate cancer trial. Stock TitanView source ↗Stock TitanSep 14, 2026neutral00.6
$JANX stock is up 7% today. Here's what we see in our data. - Quiver Quantitative$JANX stock is up 7% today. Here's what we see in our data. Quiver QuantitativeView source ↗Quiver QuantitativeAug 24, 2026neutral00.6
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - Zacks Investment ResearchJANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know Zacks Investment ResearchView source ↗Zacks Investment ResearchAug 21, 2026neutral00.6
JANX Forecast — Price Target — Prediction for 2027 - TradingViewJANX Forecast — Price Target — Prediction for 2027 TradingViewView source ↗TradingViewJun 26, 2026neutral00.6
Here's Why You Should Add JANX Stock to Your Portfolio Now - Yahoo FinanceHere's Why You Should Add JANX Stock to Your Portfolio Now Yahoo FinanceView source ↗Yahoo FinanceMay 26, 2026neutral00.6
Here's Why You Should Add JANX Stock to Your Portfolio Now - TradingViewHere's Why You Should Add JANX Stock to Your Portfolio Now TradingViewView source ↗TradingViewMay 26, 2026neutral00.6
Insider Sale: Vice President of $JANX Sells 2,038 Shares - Quiver QuantitativeInsider Sale: Vice President of $JANX Sells 2,038 Shares Quiver QuantitativeView source ↗Quiver QuantitativeMay 14, 2026neutral00.6
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking AlphaJanux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value Seeking AlphaView source ↗Seeking AlphaMay 4, 2026neutral00.6
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - StocktwitsJANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline StocktwitsView source ↗StocktwitsApr 27, 2026neutral00.6

Informational research only, not financial advice. Forecasts are uncertain and can be wrong.